High Growth Tech Stocks In The US Market November 2025

The United States market has recently seen a mix of gains and declines, with the Dow Jones Industrial Average and S&P 500 experiencing modest rises while the Nasdaq faced slight downward pressure amid fluctuating tech stock performances. In this dynamic environment, identifying high growth tech stocks requires careful consideration of factors such as innovation potential, market demand for technology solutions, and adaptability to changing economic conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 74 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

CureVac (CVAC)

Simply Wall St Growth Rating: ★★★★★☆

Overview: CureVac N.V. is a biopharmaceutical company dedicated to developing transformative medicines using mRNA technology, with a market cap of $1.13 billion.

Operations: CureVac focuses on developing transformative medicines using mRNA technology. With a market cap of approximately €1.13 billion, the company is engaged in pioneering medical advancements in the biopharmaceutical sector.

CureVac, navigating a transformative year, reported a significant dip in quarterly sales to EUR 54.13 million from EUR 493.9 million the previous year, yet maintained robust net income figures at EUR 273.23 million. This resilience is underscored by an aggressive R&D strategy, with expenditures aimed at pioneering mRNA technologies—a sector poised for rapid expansion given its application in fast-tracking vaccine development. Despite facing industry-wide challenges such as fluctuating market demands and intense competition, CureVac's strategic emphasis on innovation through research has positioned it well within the high-growth biotech landscape, especially as it looks to capitalize on its expected annual earnings growth of 77.8% and revenue surge of 33.5%. As the company prepares for a special shareholders meeting amidst an exchange offer by BioNTech SE, these financial maneuvers could significantly influence its operational dynamics and market positioning moving forward.

• Delve into the full analysis health report here for a deeper understanding of CureVac.
• Gain insights into CureVac's historical performance by reviewing our past performance report.

Arista Networks (ANET)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Arista Networks Inc develops, markets, and sells data-driven networking solutions for AI, data center, campus, and routing environments across various global regions with a market cap of $147.88 billion.

Operations: The company generates revenue primarily from its Computer Networks segment, amounting to $8.45 billion.

Arista Networks has demonstrated robust financial performance with a notable increase in third-quarter revenue to $2.31 billion, up from $1.81 billion year-over-year, accompanied by a rise in net income to $853 million from $748 million. This growth is underpinned by strategic innovations like the launch of the R4 Series platforms, enhancing AI and data center capabilities with advanced technologies such as 800 Gbps HyperPorts and integrated security features. These developments not only reduce total cost of ownership but also cater efficiently to high-capacity demands across various segments including cloud titans and service providers, setting new industry standards for network architecture optimization.

• Navigate through the intricacies of Arista Networks with our comprehensive health report here.
• Examine Arista Networks' past performance report to understand how it has performed in the past.

VTEX (VTEX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: VTEX, with a market cap of $682.31 million, offers a software-as-a-service digital commerce platform tailored for enterprise brands and retailers through its subsidiaries.

Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $234.12 million. Its business model focuses on providing a digital commerce platform for enterprise brands and retailers.

VTEX, a player in the e-commerce platform sector, has shown promising growth with third-quarter revenue rising to $59.61 million from $55.99 million year-over-year, reflecting an 11.1% increase. This growth is paired with a substantial rise in net income to $6.35 million from $3.37 million, indicating strong operational efficiency and market adaptability. The company's strategic focus on expanding its subscription base is evident as it targets FX-neutral subscription revenue growth of up to 10% for the upcoming quarter, positioning itself well within a competitive landscape that increasingly values robust digital commerce solutions. In addition to financial growth, VTEX has been proactive in capital management; between July and November 2025, it repurchased over 6 million shares for $27.59 million under its buyback program announced earlier this year—a move reflecting confidence in its financial health and future prospects. With earnings expected to grow by approximately 36% annually—outpacing broader market trends—the company's innovative approach and solid execution provide a compelling narrative of resilience and potential within the tech ecosystem.

• Dive into the specifics of VTEX here with our thorough health report.
• Assess VTEX's past performance with our detailed historical performance reports.

Summing It All Up

• Get an in-depth perspective on all 74 US High Growth Tech and AI Stocks by using our screener here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.